BENITIONSClinical Trial Intelligence

Exclusion of Intra-atrial Thrombus Before Catheter Ablation

該当なし 完了 NCT03455673

対象疾患Atrial Fibrillation, Thrombi
該当なし
スポンサーGroupe Hospitalier de la Rochelle Ré Aunis
ステータス完了
参加者数3,160 名
介入(薬剤)ATE score
開始日2018年9月18日
完了日2020年11月7日
結果公開日2023年12月22日

概要

Atrial fibrillation is the most frequent heart rhythm disorder. Its symptomatic forms, resistant to drug therapy, require invasive management (catheter ablation), which exposes to potentially serious complications including thromboembolic complications. Despite anticoagulant treatment, intra-atrial thrombus, which is a contraindication to catheter ablation, is detected in nearly 2 % of cases. Its diagnosis requires prior transoesophageal echocardiography, an unpleasant examination. A previous study (NCT02199080) showed that a zero ATE score, defined by no heart failure, no hypertension, no history of stroke, d-dimer \< 270 ng/mL, has a negative predictive value of 100 % for the exclusion of intra-atrial thrombus. The objective of the study is to confirm the negative predictive value, sensitivity and specificity of the ATE score for the exclusion of intra-atrial thrombus.

Number of Patients With Atrial Thrombus and a Zero ATE Score

at most 48 hours before ablation · Participants

Atrial Fibrillation2 Participants
Atrial Fibrillation816 Participants
Atrial Fibrillation27 Participants
Atrial Fibrillation2227 Participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。